Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Large Decline in Short Interest

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) saw a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 55,500 shares, a decline of 42.2% from the January 31st total of 96,000 shares. Based on an average trading volume of 64,900 shares, the short-interest ratio is currently 0.9 days. Approximately 3.3% of the company’s shares are sold short.

Institutional Trading of Lixte Biotechnology

A hedge fund recently bought a new stake in Lixte Biotechnology stock. Atlas Legacy Advisors LLC acquired a new position in shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 12,707 shares of the company’s stock, valued at approximately $26,000. Atlas Legacy Advisors LLC owned about 0.56% of Lixte Biotechnology as of its most recent SEC filing. 5.10% of the stock is currently owned by institutional investors and hedge funds.

Lixte Biotechnology Price Performance

LIXT traded down $0.09 during trading on Monday, hitting $1.21. The company’s stock had a trading volume of 33,298 shares, compared to its average volume of 317,221. The firm’s 50 day moving average price is $2.09 and its 200-day moving average price is $1.95. The stock has a market cap of $2.72 million, a PE ratio of -0.70 and a beta of -0.04. Lixte Biotechnology has a twelve month low of $1.21 and a twelve month high of $4.40.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.